GICS Sector : Healthcare
EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom.The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery.It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye.
EyePoint reported a net loss of $68 million, or $0.81 per share, up from $41 million ($0.64) in 2024, while operating expenses rose to $71 million from $57 million. Cash and investments topped $306 million, a boost from a $173 million follow‑on financing. Valuation metrics reflect a P/E of –5.3, a P/S of 39.39, and an EV/EBITDA of –4.82, underscoring the company’s pre‑revenue, high‑growth profile. “We ended 2025 with a strong balance sheet of $306 million in cash and investments,” the staff noted, highlighting the runway to 2027.
Publication Date: Apr -17
The first patients in both Phase 3 DME trials received DuraVu, with safety data showing no signals in over 190 participants across four completed studies. The Phase 3 wet AMD program, designed to mirror real‑world practice, compares DuraVu to on‑label aflibercept, positioning the drug as a potential first‑to‑market sustained‑release therapy in two of the largest retinal markets.
Michael Campbell’s appointment as Chief Commercial Officer brings experience from Lucentis and Xiidra launches. Campbell outlined a comprehensive go‑to‑market strategy focused on positioning, pricing research, patient access, and post‑launch services, aimed at a U.S. launch contingent on positive Phase 3 outcomes.
EyePoint follows a noninferiority framework with a hierarchical test for superiority in both wet AMD and DME studies. Independent data monitoring committees conduct masked reviews, with the last meeting in November and the next scheduled for May. Biomarker work on IL‑6 and JAK1 is slated for presentation at ARVO, reinforcing the drug’s multi‑mechanistic narrative.
Analyst estimates project revenue growth of 4,471.6% next year if the company achieves commercial launch, driven by a $10 billion combined market for wet AMD and DME. The robust safety profile, coupled with a strong cash position, positions EyePoint to fund operations through 2027 and potentially secure a best‑in‑class market share once regulatory approval is obtained.
EyePoint to Report First Quarter 2026 Financial Results on May 6, 2026
Apr -29
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Insider Ramiro Ribeiro Sells 2,437 Shares of Stock
Apr -21
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Apr -16
Aberdeen Group plc Has $29.34 Million Position in Eyepoint Pharmaceuticals, Inc. $EYPT
Apr -06
EyePoint Pharmaceuticals Teases August Phase 3 Wet AMD Data for DURAVYU at RBC Ophthalmology Conference
Mar -27
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Mar -16
This Biotech Stock Up Nearly 100% in a Year Has Drawn a New $20 Million Share Investment
Mar -15
Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Average Recommendation of “Buy” by Analysts
Mar -13
EyePoint Pharmaceuticals' 9.27% growth in License and Collaboration Agreements is driven by increasing demand for ophthalmic treatments, strategic partnerships, and expansion into new markets. The company's innovative pipeline and strong intellectual property portfolio also contribute to its growth, as well as its ability to secure lucrative licensing deals with major pharmaceutical companies.
EyePoint Pharmaceuticals' 8.9% growth in Ophthalmic Products is driven by increasing demand for innovative treatments, expanding indications for existing products, and strategic partnerships. Growing prevalence of eye diseases, such as diabetic retinopathy and age-related macular degeneration, also contribute to the segment's growth.
Strong demand for EyePoint's ophthalmic products, particularly YUTIQ and DEXYCU, drives royalty growth. Increasing adoption in the U.S. and expansion into international markets contribute to the 8.9% growth. Additionally, the company's strategic partnerships and collaborations, such as with Ocumension Therapeutics, further boost revenue.
DEXYCU is a corticosteroid indicated for the treatment of postoperative inflammation and pain associated with ocular surgery.
YUTIQ is a fluocinolone acetonide intravitreal implant indicated for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye.
ILUVIEN is a fluocinolone acetonide intravitreal implant indicated for the treatment of diabetic macular edema (DME) in patients who have an artificial lens implanted.
EyePoint Pharmaceuticals, Inc. has a moderate threat of substitutes due to the presence of alternative treatments and therapies for eye diseases.
EyePoint Pharmaceuticals, Inc. has a low bargaining power of customers due to the lack of negotiating power of individual patients and the presence of insurance companies.
EyePoint Pharmaceuticals, Inc. has a moderate bargaining power of suppliers due to the presence of multiple suppliers of raw materials and equipment.
EyePoint Pharmaceuticals, Inc. has a high threat of new entrants due to the growing demand for eye care treatments and the presence of venture capital funding for startups.
EyePoint Pharmaceuticals, Inc. operates in a highly competitive industry with several established players, leading to a high intensity of rivalry.
| Value | |
|---|---|
| Debt Weight | 2.01% |
| Debt Cost | 12.54% |
| Equity Weight | 97.99% |
| Equity Cost | 12.54% |
| WACC | 12.54% |
| Leverage | 2.05% |
Value: 7.0
Growth: 7.2
Quality: 6.0
Yield: 0.0
Momentum: 5.0
Volatility: 4.0
1-Year Total Return ->
Value: 6.0
Growth: 4.0
Quality: 4.1
Yield: 0.0
Momentum: 9.0
Volatility: 4.7
1-Year Total Return ->
Value: 6.2
Growth: 5.0
Quality: 4.4
Yield: 0.0
Momentum: 8.5
Volatility: 2.0
1-Year Total Return ->
Value: 4.5
Growth: 4.8
Quality: 4.7
Yield: 0.0
Momentum: 7.0
Volatility: 3.3
1-Year Total Return ->
Value: 6.2
Growth: 2.2
Quality: 4.9
Yield: 0.0
Momentum: 9.5
Volatility: 1.3
1-Year Total Return ->
Value: 7.7
Growth: 6.8
Quality: 2.7
Yield: 0.0
Momentum: 3.0
Volatility: 2.3
1-Year Total Return ->